期刊文献+

新型骨显像剂^(99)Tc^m-HBIDP的制备与初步生物学性质

Preparation and Biological Study on a Novel Bone Imaging Agent ^(99)Tc^m-HBIDP
下载PDF
导出
摘要 在SnCl2.2H2O存在下,用Na 99 TcmO4标记1-羟基-2-(1-丁基-1H-咪唑-2-基)亚乙基-1,1-双膦酸(HBIDP)。研究了99 Tc m-HBIDP的最优标记条件、理化性质及其在正常小鼠体内分布。结果表明,当pH=6、m(SnCl2.2H2O)=100μg、m(HBIDP)=5mg、A(99 TcmO4-)=55.5MBq、室温反应15min时,99 Tcm-HBIDP的标记率大于95%。99 Tcm-HBIDP在pH为7.0和7.4时,脂水分配系数lg P分别为-2.17和-2.28。99 Tcm-HBIDP的血浆蛋白结合率为(31.41±1.25)%。99 Tcm-HBIDP具有良好的体外稳定性。动物分布实验显示:99 Tcm-HBIDP在骨组织中有较高摄取,并能保持较长时间;其在软组织中的摄取相对较低,并能较快的清除。此外,99 Tcm-HBIDP较99 Tcm-ZL在心、肝、脾等器官组织中的摄取低。99 Tcm-HBIDP有望成为新型骨显像剂。 To obtain a maximum radiolabeling yield,the labeling parameters for 99Tcm-HBIDP were optimized.Chemical and physical properties and biodistribution studies in mice for 99Tcm-HBIDP were performed.The optical labeling parameters are found as follows:pH=6,m(SnCl2·2H2O)=100 μg,m(HBIDP)=5 mg,A(99TcmO-4)=55.5 MBq at room temperature for 15 min and the radiochemical purity is more than 95% and it is stable within 6 h in vitro at room temperature.The octanol-water partition coefficients of 99Tcm-HBIDP(lg P) are-2.17 and-2.28 at the pH value of 7.0 and 7.4,respectively.The plasma protein binding ratio of 99Tcm-HBIDP is(31.41±1.25)%.In the biodistribution studies,99Tcm-HBIDP exhibits a relatively high uptake in bone and much lower uptake in soft tissues and shows rapid clearance from soft tissues.Besides,the uptake of 99Tcm-HBIDP in heart,liver and spleen is much lower than that of 99Tcm-ZL.These preliminary studies indicate that 99Tcm-HBIDP has significant potential as a novel bone imaging agent.
出处 《核化学与放射化学》 CAS CSCD 北大核心 2012年第2期93-101,共9页 Journal of Nuclear and Radiochemistry
基金 国家自然科学基金资助项目(20801024) 江苏省自然科学基金资助项目(BK2009077) 江苏省卫生厅科研项目(H200963)
关键词 99Tcm-HBIDP 标记 理化性质 动物分布 骨显像剂 99Tcm-HBIDP radiolabeling chemical and physical property biodistribution bone imaging agent
  • 相关文献

参考文献5

二级参考文献37

  • 1罗世能,王洪勇,谢敏浩,刘晓亚,叶万忠,陈志明,冯瑛瑛,曹国宪.~99Tc^m-MIDP的制备及其生物学分布[J].中华核医学杂志,2005,25(6):341-343. 被引量:11
  • 2崔巍,彭六保.唑来膦酸的临床应用研究进展[J].中南药学,2006,4(6):467-469. 被引量:19
  • 3吴宁,葛才荣.双膦酸盐类药物的临床应用进展[J].中国误诊学杂志,2007,7(16):3707-3709. 被引量:6
  • 4Fleisch H, Russell RGG. Bisaz S, et al. Calcif Tissue Res, 1968, 2: 10-10A.
  • 5Vasireddy S, Talwakar A, Miller H, et al. Clin Rheumatol, 2003, 22: 376-380.
  • 6Dawson N A. Expert Opin Pharmacother, 2003, 4: 705-716.
  • 7SUN Da. Skeletal imaging of radionuclide. Hangzhou: Zhejiang University Press (in Chinese), 2000: 12-24.
  • 8Widler L, Jaeggi K A, Glatt M, et al. J Med Chem, 2002, 45: 3721-3738.
  • 9WANG Hongyong, LUO Shineng, XIE Minhao, et al. Nucl Tech (in Chinese), 2006, 29(6): 438-441.
  • 10Asikoglu M, Durak F G Appl Radiat Isot, 2009, 67: 1616-1621.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部